Skip to main content

Plasticidad tumoral y la regulación de anhidrasa carbónica 9 en carcinoma hepatocelular. Base racional para modular la evasión inmunológica y mejorar la respuesta al tratamiento

PI22/01427

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i en Salud
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
Execution centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Evolving epidemiology of HCC in Spain

  • Sala Llinas, Margarita|||0000-0003-4879-1780
  • Pascual, Sonia|||0000-0002-4265-5019
  • Rota Roca, Maria Rosa
  • Matilla, Ana María
  • Campos, Marta
  • Delgado, Manuel
  • Ferrer, María Teresa
  • Montero, José Luís
  • González Santiago, Jesús M.|||0000-0003-4667-4492
  • Guerrero, Antonio
  • Aracil, Carlos|||0000-0002-8228-9041
  • Rodríguez Lope, Carlos|||0000-0002-6713-8800
  • Romero-Gutiérrez, Marta
  • Sogbe, Miguel|||0000-0002-2846-7812
  • Vázquez Rodríguez, Sergio|||0000-0001-6108-9449
  • Fuentes Olmo, Javier|||0000-0001-8637-510X
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Cortés-García, Luis|||0000-0003-3164-2703
  • Vallejo-Senra, N.
  • Rendón, Paloma|||0000-0002-6521-3766
  • Clos, Ariadna|||0000-0002-6414-2097
  • Díaz-Bethencourt, D.
  • García Sánchez, Araceli
  • Quiñones Castro, Raisa|||0000-0003-2446-9068
  • Bustamante, Javier|||0000-0002-5280-3038
  • Perelló, Christie|||0000-0003-0234-2330
  • Urquijo Ponce, J.J.
  • Andreu Serra, Hernán
  • Llamoza-Torres, Camilo J.|||0000-0001-8072-9413
  • Montoliu, Silvia|||0000-0002-3041-578X
  • Fernández Marcos, Cristina
  • Guiberteau, A.
  • Hernandez-Guerra, Manuel|||0000-0002-3478-9981
  • Vergara, Mercedes|||0000-0002-6971-8657
  • Fernández-López, A.M.
  • Valer López-Fando, M.P.
  • Gutiérrez-García, M.L.
  • Hernáez-Alsina, T.|||0000-0002-3734-2448
  • Coll, Susanna|||0000-0002-0395-9685
  • Cuyàs, Berta|||0000-0001-9988-7163
  • Morillas, M.J.
  • Rebolledo Olmedo, Susana
  • Fernández Bermejo, Miguel
  • Roget, Mercè
  • Calvo Ramos, Irina
  • Pacheco del Río, G.
  • Rifà, Raimon|||0000-0003-1911-3681
  • Conde Gacho, Pilar
  • Llorente Barrio, Mónica|||0000-0003-0267-989X
  • Gómez-Rubio, M.
  • Peñas, Irene
  • Serra Matamala, Isabel|||0000-0002-5694-9325
  • Cachero, Alba|||0000-0002-0010-4534
  • Reig, María|||0000-0002-5711-9534
  • Giráldez-Gallego, Álvaro|||0000-0001-6849-9272
  • Guerrero Misas, Marta
  • Segarra, J.X.|||0000-0002-7222-5191
  • Lledó, J.L.
  • Díaz-González, Álvaro|||0000-0003-3610-2263
  • Delgado, Carolina|||0000-0002-0808-4494
  • Iñarrairaegui, M.
  • Rodríguez-González, M.M.
  • Lázaro, M.
  • Bermúdez-Ramos, María|||0000-0002-5516-3902
  • Lué, A.|||0000-0002-9672-6038
  • Molina, E.
  • Macías-Rodríguez, M.A.|||0000-0003-2634-6125
  • Rodríguez, Manuel|||0000-0001-5763-7668
  • Chiminazzo, V.
  • Varela Calvo, Maria|||0000-0003-4288-2593
Background & Aims: The epidemiological landscape of hepatocellular carcinoma (HCC) in Europe is evolving. This study aims to provide an updated description of the current epidemiology of liver cancer in Spain. Methods: This multicenter prospective study collected demographic and clinical data on primary liver cancer between October 2022 and January 2023. We conducted descriptive and comparative analyses with data collected in 2008 and 2014. Results: Of the 767 cases of primary liver cancer collected from 52 centers, 91% were diagnosed as HCC. The majority of patients were male (83.3%), average age 68 years, 80.7% had cirrhosis. The primary causes were alcohol (29.9% alone, 55% combined with other etiologies), liver disease related to metabolic syndrome (LDrMS, 23%) and hepatitis C (17.3%). Treatments included ablation (15.7%), systemic therapy (14.7%), and chemoembolization (14.6%). Data from 29 centers (n = 1,351) across three registries revealed a significant increase in LDrMS (from 4.9% to 24%) and HCC in non-cirrhotic livers (from 4.2% to 7.9%). Meanwhile, hepatitis C decreased sharply (from 43% to 17.5%). Alcohol-related cases remained stable. There was a slight increase in male patients and hypertension, diabetes, and obesity. Patients with cirrhosis diagnosed outside of screening programs presented with larger tumors and more advanced disease. This led to fewer evaluations for curative treatments. Conclusions: Alcohol accounts for 30% of HCC cases and is the main etiology. The registry shows a decrease in hepatitis C-related HCC, an increase in LDrMS and HCC in non-cirrhotic livers. Surveillance was implemented in ∼80% of the recommended population. There is a need for improved screening and prevention strategies, particularly for alcohol abuse and LDrMS, to enhance HCC management. Impact and implications: Our study showcases the involvement of numerous reference centers across Spain and examines over 1,300 patients to track the changing epidemiology of hepatocellular carcinoma (HCC) over 14 years. In patients with known liver cirrhosis, more than 80% of HCC diagnoses were made through screening leading to early-stage identification and curative treatment opportunities. Notably, there has been a shift in HCC etiology within the registries from hepatitis C to liver disease related to metabolic syndrome, with an increase in cases without cirrhosis. Findings indicate a need for the prevention and early detection of HCC, particularly focusing on alcohol and liver disease related to metabolic syndrome, along with greater involvement of health authorities, to improve the participation of at-risk patients in screening programs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical Trial, Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)

  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Matilla, Ana
  • Lledó-Navarro, José Luis|||0000-0001-7973-3503
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Varela Calvo, Maria|||0000-0003-4288-2593
  • Iñarrairaegui, Mercedes|||0000-0001-9180-4693
  • Perelló, Christie|||0000-0003-0234-2330
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Llarch, Neus|||0000-0003-3209-0453
  • Márquez, Laura
  • Guerrero, Antonio
  • Iserte, Gemma|||0000-0003-3908-8743
  • Castaño-García, Andrés|||0000-0002-7921-9026
  • Carrión, Laura
  • Fortuny, Marta
  • Rimola, Jordi|||0000-0002-1814-4198
  • García Criado, Ángeles|||0000-0003-3536-4288
  • Domenech, Gema
  • Torres, Ferran|||0000-0002-7355-7913
  • Ríos, José|||0000-0002-0716-8784
  • Boix, Loreto|||0000-0002-6015-3901
  • Samper, Esther
  • Kateb, Àngels
  • Bruix, Jordi|||0000-0002-9826-0753
  • Reig, María|||0000-0002-5711-9534
BACKGROUND & AIMS: Highly effective second-line treatments for hepatocellular carcinoma remain an unmet need. The GOING investigator-initiated Phase I/IIa trial evaluated regorafenib plus nivolumab (add-on) in patients who progressed on sorafenib (Cohort-A) or discontinued atezolizumab-bevacizumab (Cohort-B). METHODS: Patients received regorafenib for two 28-day cycles, adding nivolumab in cycle 3, until unacceptable adverse events, symptomatic progression, withdrawal or death. Primary endpoint was safety. Secondary endpoints included overall survival, time to progression, post-progression survival, objective response rate and incidence of new-extrahepatic-spread. RESULTS: Of 85 patients screened, 67 were enrolled (75.5% BCLC-C). All experienced adverse events and 9% led to discontinuation. Severe treatment-related adverse events occurred in 28.4% overall, 32.1% in Cohort-A, and 14.3% in Cohort-B. Median overall survival was 20.0 (95% CI 11-37) months, with 40.6% survival at 36 months. In Cohort-A, median overall survival was 25 (95% CI 14-39) months with 45% survival at 36 months, while Cohort-B median overall survival was 8 (95% CI 4-NE) months with 28.6% survival at 24 months. Objective response rate was 16.4%; median time to progression and post-progression survival were 5 (95% CI 4-9) months and 14 (95% CI 8-33) months. Intrahepatic growth was the most common progression pattern, followed by new-extrahepatic-spread. CONCLUSIONS: The add-on strategy of regorafenib plus nivolumab in second-line had manageable safety and significant clinical activity with a noteworthy median overall survival of 20 months. Among those progressing on sorafenib, 45% were alive at 3 years. These findings support further evaluation with mechanism-guided trials after progression on immunotherapy. TRIAL REGISTRATION: EudraCT number: 2019-003108-10; https://www.clinicaltrialsregister.eu.